SCHEMBL5714975

SCHEMBL5714975

O=C(O)c1ccc(N2CCN(C(=O)Oc3ccc(CCSc4ncc[nH]4)cc3)CC2)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.40
PANK3 Q9H999 1/20 0.40
ME2 P23368 7/20 0.39
ME1 P48163 7/20 0.39
ME3 Q16798 7/20 0.39
SMO Q99835 1/20 0.39
HDAC1 Q13547 1/20 0.39
SLC6A7 Q99884 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
SCD O00767 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5715347 0.91 HRH3 (0.41) HRH3PANK3ME2ME1ME3
SCHEMBL5904372 0.90 PANK3 (0.40) PANK3ME2ME1ME3GPR119
SCHEMBL5714722 0.89 PANK3 (0.42) HRH3PANK3ME2ME1ME3
SCHEMBL5715038 0.89 ME2 (0.43) PANK3ME2ME1ME3GPR119
SCHEMBL5715128 0.89 ME2 (0.43) HRH3PANK3ME2ME1ME3
SCHEMBL5714815 0.87 HRH3 (0.42) HRH3PANK3ME2ME1ME3
SCHEMBL5715018 0.86 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL5714821 0.86 MGLL (0.36) ALDH1A1CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5714943 0.86 HSD17B10 (0.49) ALDH1A1TSHRSMN1; SMN2CYP1A2CYP3A4
SCHEMBL5715427 0.84 FAAH (0.41) HRH3ALDH1A1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HRH3 1098/4885PANK3 1247/4885ME2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.